Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.
Roberto Ruiz-CorderoJunsheng MaAbha KhannaGenevieve LyonsWaree RinsurongkawongRoland BassettMing GuoMark J RoutbortJianjun ZhangFerdinandos SkoulidisJohn HeymachEmily B RoartyZhenya TangL Jeffrey MedeirosKeyur P PatelRajyalakshmi LuthraSinchita Roy-ChowdhuriPublished in: BMC cancer (2020)
The mutational status of EGFR, KRAS, and TP53 can be used to easily classify lung adenocarcinoma patients into seven subtypes that show a relationship with prognosis, especially in patients who underwent surgery, and these subtypes are similar to classifications based on more complex genomic methods reported previously.